Cargando…
HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360167/ https://www.ncbi.nlm.nih.gov/pubmed/37483605 http://dx.doi.org/10.3389/fimmu.2023.1216610 |
_version_ | 1785076042898079744 |
---|---|
author | Wan, Xin Young, Ken H. Bai, Ou |
author_facet | Wan, Xin Young, Ken H. Bai, Ou |
author_sort | Wan, Xin |
collection | PubMed |
description | Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-line immunochemotherapy regimens, and worse clinical prognosis. HBV-associated DLBCL often exhibits abnormal activation of the nuclear factor kappa B pathway as well as mutations in oncogenes, including Myc and BCL-6. Currently, there is no consensus on any specific and effective treatment for HBV-associated DLBCL. Therefore, in this review, we comprehensively and mechanistically analyzed the natural history of HBV infection and immunity, including HBV-mediated oncogenes, immune escape, epigenetic alterations, dysregulated signaling pathways, and potential therapeutic approaches for HBV-associated DLBCL. We hope that an improved understanding of the biology of HBV-associated DLBCL would lead to the development of novel therapeutic approaches, enhance the number of effective clinical trials, and improve the prognosis of this disease. |
format | Online Article Text |
id | pubmed-10360167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103601672023-07-22 HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy Wan, Xin Young, Ken H. Bai, Ou Front Immunol Immunology Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-line immunochemotherapy regimens, and worse clinical prognosis. HBV-associated DLBCL often exhibits abnormal activation of the nuclear factor kappa B pathway as well as mutations in oncogenes, including Myc and BCL-6. Currently, there is no consensus on any specific and effective treatment for HBV-associated DLBCL. Therefore, in this review, we comprehensively and mechanistically analyzed the natural history of HBV infection and immunity, including HBV-mediated oncogenes, immune escape, epigenetic alterations, dysregulated signaling pathways, and potential therapeutic approaches for HBV-associated DLBCL. We hope that an improved understanding of the biology of HBV-associated DLBCL would lead to the development of novel therapeutic approaches, enhance the number of effective clinical trials, and improve the prognosis of this disease. Frontiers Media S.A. 2023-07-07 /pmc/articles/PMC10360167/ /pubmed/37483605 http://dx.doi.org/10.3389/fimmu.2023.1216610 Text en Copyright © 2023 Wan, Young and Bai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wan, Xin Young, Ken H. Bai, Ou HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy |
title | HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy |
title_full | HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy |
title_fullStr | HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy |
title_full_unstemmed | HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy |
title_short | HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy |
title_sort | hbv-associated dlbcl of poor prognosis: advance in pathogenesis, immunity and therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360167/ https://www.ncbi.nlm.nih.gov/pubmed/37483605 http://dx.doi.org/10.3389/fimmu.2023.1216610 |
work_keys_str_mv | AT wanxin hbvassociateddlbclofpoorprognosisadvanceinpathogenesisimmunityandtherapy AT youngkenh hbvassociateddlbclofpoorprognosisadvanceinpathogenesisimmunityandtherapy AT baiou hbvassociateddlbclofpoorprognosisadvanceinpathogenesisimmunityandtherapy |